ImmuCell Corporation reported unaudited financial results for the quarter ended June 30, 2026. Revenue increased 11.5% to $7.2 million, while net income rose to $1.8 million, or $0.20 per diluted share, compared to $0.5 million in the prior year period. The earnings improvement was significantly aided by a one-time $2 million legal settlement payment from a former contract manufacturer. Gross margin declined to 34% due to lower manufacturing volumes and absorbed costs from a discontinued program. Cash on hand increased to $8.9 million, supported by the settlement and operating cash flows of $6.6 million for the first half of the year. The company is an animal health biologics firm that develops, manufactures, and markets products to improve calf health and productivity.

ImmuCell Corporation announced a 11.5% increase in product sales for the second quarter of 2026 compared to the second quarter of 2025, according to preliminary, unaudited sales results. ImmuCell Corporation is a biotechnology company that develops and manufactures products for immune system regulation and regulation of the immune response.

On June 4, 2026, ImmuCell's Board of Directors authorized a manufacturing capacity expansion program to pivot from in-house Re-Tain® production to expanded First Defense® production. The first phase begins immediately, involving the renovation of the former Re-Tain® facility and the addition of a new freeze dryer, with an estimated cost of $3.5 million and a 12-month timeline. A second phase will repurpose equipment and add automation to increase colostrum processing capacity. ImmuCell is a biotechnology company that develops and manufactures animal health products.